Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-901 Monotherapy and Combination Therapy in Ovarian Cancer
NCT07278336Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of cusp06 in ovarian cancer (8 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events and Overall Response (as assessed by the investigator). Started Nov 2025; status: recruiting.
02
Drugs
cusp06
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07278336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278336.